

Filed 12/2/03

10/725,267

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	00/946,698 10/725,267
		Filing Date	03/29/2001
Date Submitted: (use as many sheets as necessary)		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned 1624
Sheet 1 of 14		Examiner Name	Unassigned T. TRUONG
		Attorney Docket Number	034536-0906

U.S. PATENT DOCUMENTS							Class/subclass
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages* Columns/ Lines, Where Relevant Passages or Relevant Figures Appear	
		Number	Kind Code ² (if known)				
TNT ✓	A1	Re. 36,256	E	Spada et al.	07-20-1999	514/249	
	✓ A2	4,002,749		Rovnyak	01-11-1977	424/246	
	✓ A3	4,053,613		Rovnyak et al.	10-11-1977	424/246	
	✓ A4	4,966,849		Vallee et al.	10-30-1990	435/199	
	✓ A5	5,196,446	A	Levitzki et al.	03-23-1993	514/415	
	✓ A6	5,217,999	A	Levitzki et al.	06-08-1993	514/613	
	✓ A7	5,302,606	A	Spada et al.	04-12-1994	514/357	
	✓ A8	5,322,950	A	Sircar et al.	06-21-1994	548/253	
	✓ A9	5,330,992	A	Eissenstat et al.	07-19-1994	514/312	
	✓ A10	5,397,787	A	Buzzetti et al.	03-14-1995	514/300	
	✓ A11	5,786,488	A	Tang et al.	07-28-1998	548/455	
	✓ A12	5,792,783	A	Tang et al.	08-11-1998	514/397	
	✓ A13	5,880,141	A	Tang et al.	03-09-1999	514/339	
	✓ A14	5,883,113	A	Tang et al.	03-16-1999	514/418	
	✓ A15	5,883,116	A	Tang et al.	03-16-1999	514/418	
TNT ✓	A16	5,886,020	A	Tang et al.	03-23-1999	514/418	

Examiner Signature		Date Considered	2/3/06
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: (use as many sheets as necessary)				Complete if Known Application Number <u>09/040,609- 10/725,767</u> Filing Date <u>03/29/2001</u> First Named Inventor <u>Peng Cho TANG</u> Group Art Unit <u>Unassigned 1624</u> Examiner Name <u>Unassigned T. TRUONG</u> Attorney Docket Number <u>034536-0908</u>	
Sheet	2	of	14		

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
TNT ✓	A17	WO	91/13055	A2	FARMITALIA CARLO ERBA SRL	09-05-1991	_____	
	A18	WO	91/15495	A1	PFIZER INC.	10-17-1991	_____	
	✓ A19	WO	92/07830	A2	PFIZER INC.	05-14-1992	_____	
	✓ A20	WO	92/20642	A1	RHONEPOULENC RORER INTERNATIONAL	11-26-1992	_____	
	✓ A21	WO	92/21660	A1	PFIZER INC.	12-10-1992	_____	
	✓ A22	WO	93/23040	A1	MERCK & CO., INC.	11-25-1993	_____	
	✓ A23	WO	94/03427	A1	WARNER-LAMBERT COMPANY	02-17-1994	_____	
	✓ A24	WO	94/10202	A1	GENENTECH, INC.	05-11-1994	_____	
	✓ A25	WO	94/14808	A1	FARMITALIA CARLO ERBA SRL	07-07-1994	_____	
	✓ A26	WO	95/14667	A1	PFIZER INC.	06-01-1995	_____	
	✓ A27	WO	95/24190	A2	SUGEN, INC.	09-14-1995	_____	
	✓ A28	WO	96/00226	A1	PHARMACIA S.P.A.	01-04-1996	_____	
	✓ A29	WO	96/16964	A1	PHARMACIA S.P.A.	06-06-1996	_____	
	✓ A30	WO	96/22976	A1	PHARMACIA S.P.A.	08-01-1996	_____	
	✓ A31	WO	96/40116	A1	SUGEN, INC.	12-19-1996	_____	
	✓ A32	WO	98/07695	A1	SUGEN, INC.	02-26-1998	_____	
	✓ A33	WO	98/07835	A2	SUGEN, INC.	02-26-1998	_____	
TNT ✓	A34	WO	98/45708	A1	SUGEN, INC.	10-15-1998	_____	

Examiner Signature		Date Considered	2/3/06
--------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: (use as many sheets as necessary)		Application Number	607818-888 10/725, 267
		Filing Date	03/29/2001
		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned 1624
		Examiner Name	Unassigned T. TRUONG
Sheet	3	of	14
		Attorney Docket Number	034538-0908

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
TNT	✓ A35	WO	98/50358	A1	SUGEN, INC.	11-12-1998		
	✓ A36	WO	98/56376	A1	SUGEN, INC.	12-17-1998		
	✓ A37	WO	99/10325	A1	GLAXO GROUP LIMITED	03-04-1999		
	✓ A38	EP	0 252 713	B1	PFIZER INC.	01-13-1988		
	✓ A39	EP	0 566 226	B1	ZENECA LIMITED	10-20-1993		
	✓ A40	FR	1.398.224		IMPERIAL CHEMICAL INDUSTRIES LIMITED	05-07-1965		X
TNT	✓ A41	HU	3899/92		RICHTER GEDEON VEGYESZETI GYAR RT	12-10-1992		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
TNT	✓ A42	AKBASAK and SUNAR-AKBASAK, "Oncogenes: cause or consequence in the development of glial tumors," <i>J. Neurol. Sci.</i> 111:119-133 (1992) © Elsevier Science Publishers.	
	✓ A43	ANDREANI et al., "Synthesis and potential coanthracyclinic activity of substituted 3-(5-imidazo[2,1-b]thiazolymethylene)-2-indolinones," <i>Eur. J. Med. Chem.</i> 32:919-924 (1997) © Elsevier, Paris.	
	✓ A44	ANDREANI et al., "In Vivo Cardiotonic Activity of Pyridylmethylene-2-indolinones," <i>Arzneimittel-Forschung Drug Research</i> 48:727-729 (1998) ©.	
TNT	✓ A45	ARTEAGA et al., "Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice," <i>J. Clin. Invest.</i> 84:1418-1423 (1989) copyright The American Society for Clinical Investigation, Inc.	

Examiner Signature		Date Considered	2/3/06
--------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: (use as many sheets as necessary)		Application Number	09/810,698 10/725,267
		Filing Date	03/29/2001
		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned 1624
		Examiner Name	Unassigned T. TRUONG
Sheet	4	of	14
		Attorney Docket Number	034536-0906

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
TMT	A46	ARVIDSSON et al., "Tyr-716 in the Platelet-Derived Growth Factor β -Receptor Kinase Insert is Involved in GRB2 Binding and Ras Activation," <u>Molecular and Cellular Biology</u> 14:6715-6726 (1994) © The American Society for Microbiology .	
	A47	BASERGA, "Oncogenes and the Strategy of Growth Factors," <u>Cell</u> 79:927-930 (1994) © Cell Press .	
	A48	BASERGA, "The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?" <u>Cancer Research</u> 55:249-252 (1995) .	
	A49	Beilstein Reg. No. 252929 (1998) .	
	A50	BOLEN et al., "The Src family of tyrosine protein kinases in hemopoietic signal transduction," <u>FASEB J.</u> 6:3403-3409 (1992) .	
	A51	BOLEN, "Nonreceptor tyrosine protein kinases," <u>Oncogene</u> 8:2025-2031 (1993) copyright MacMillan Press Ltd.	
	A52	BONNER et al., "Structure and Biological Activity of Human Homologs of the <i>rat/mil</i> Oncogene," <u>Molecular and Cellular Biology</u> 5:1400-1407 (1985) © The American Society for Microbiology .	
	A53	BUZZETTI et al., "Cinnamamide Analogs as Inhibitors of Protein Tyrosine Kinases," <u>J. Pharmacol</u> 48:615-638 (1993) .	
TMT	A54	CANCE et al., "Novel Protein Kinases Expressed in Human Breast Cancer," <u>Int. J. Cancer</u> 54:571-577 (1993) © Wiley-Liss, Inc.	

Examiner Signature		Date Considered	2/3/06
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/10,508 10/725,267
		Filing Date	03/29/2001
Date Submitted:		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned 1629
(use as many sheets as necessary)		Examiner Name	Unassigned T. TRUONG
		Attorney Docket Number	034536-0906
Sheet	5	of	14

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
TNT ✓	A55	CARPENEDO et al., "Identification and Measurement of Oxindole (2-Indolinone) in the Mammalian Brain and Other Rat Organs," <u>Analytical Biochemistry</u> 244:74-79 (1997) © Academic Press, Inc.	
✓	A56	CHEN et al., "Effects of 3,3-Dipyridylmethyl-1-Phenyl-2-Indolinone on γ-Aminobutyric Acid Elicited Chloride Current of Snail Central Neuron," <u>Chinese Journal of Physiology</u> 40:149-156 (1997) .	
✓	A57	CLAESSON-WELSH, "Signal Transduction by the PDGF Receptors," <u>Progress in Growth Factor Research</u> 5:37-54 (1994) © Elsevier Science Ltd.	
✓	A58	COPPOLA et al., "A Functional Insulin-Like Growth Factor I Receptor Is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor," <u>Molecular and Cellular Biology</u> 14:4588-4595 (1994) © The American Society for Microbiology .	
✓	A59	DAMIANI et al., "Inhibition of Copper-Mediated Low Density Lipoprotein Peroxidation by Quinoline and Indolinone Nitroxide Radicals," <u>Biochemical Pharmacology</u> 48:1155-1161 (1994) copyright Elsevier Science Ltd.	
✓	A60	DAVIS et al., "Synthesis and Microbiological Properties of 3-Amino-1-Hydroxy-2-Indolinone and Related Compounds," <u>Journal of Medicinal Chemistry</u> 16:1043-1045 (1973) © American Chemical Society .	
✓	A61	DE VRIES et al., "The fms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," <u>Science</u> 255:989-991 (1992) .	
✓	A62	DECKER and LOHMANN-MATTHES, "A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity," <u>J. Immunol. Methods</u> 15:61-69 (1988) copyright Elsevier .	
TNT ✓	A63	DICKSON et al., "13. Tyrosine kinase receptor - nuclear protooncogene interactions in breast cancer," <u>Cancer Treatment Res.</u> 61:249-273 (1992) © Kluwer Academic Publishers .	

Examiner Signature		Date Considered	2/3/06
--------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.


*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: (use as many sheets as necessary)		Application Number	00/846,608 — 10/725,267
		Filing Date	03/29/2001
		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned 1624
		Examiner Name	Unassigned T. TRULON
Attorney Docket Number	034536-0906		
Sheet	6	of	14

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
TNT	A64	FANTL et al., "Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules That Mediate Different Signaling Pathways," <u>Cell</u> 69:413-423 (1992) © Cell Press .	
	A65	FENDLY et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product," <u>Cancer Research</u> 50:1550-1558 (1990); © American Association for Cancer Research .	
	A66	FERRARA and HENZEL, "Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells," <u>Biochemical and Biophysical Research Communications</u> 161:851-858 (1989) © Academic Press, Inc.	
	A67	FINGL and WOODBURY, "Chapter 1 - General Principles," in <u>The Pharmacological Basis of Therapeutics</u> 5th edition, Goodman and Gilman editors, MacMillan Publishing Co., Inc., New York , pp. 1-46 (1975) © MacMillan Publishing Co. Inc.	
	A68	FLOEGE et al., "Factors involved in the regulation of mesangial cell proliferation <i>in vitro</i> and <i>in vivo</i> ," <u>Kidney International</u> 43:S47-S54 (1993) © International Society of Nephrology .	
	A69	FOLKMAN and SHING, "Angiogenesis," <u>J. Biol. Chem.</u> 267:10931-10934 (1992) © The American Society for Biochemistry and Molecular Biology .	
	A70	FOLKMAN, "Ch. 24. Angiogenesis," <u>Congress of Thrombosis and Haemostasis</u> (Verstraete et al., eds.) Leuven University Press, Leuven pp. 583-596 (1987),	
	A71	FOLKMAN, "Tumor Angiogenesis: Therapeutic Implications," <u>New England J. Medicine</u> 285:1182-1186 (1971) .	
TNT	A72	FOLKMAN, "What is the Evidence that Tumors are Angiogenesis Dependent?" <u>Journal of the National Cancer Institute</u> 82:4-6 (1990) .	

Examiner Signature		Date Considered	2/3/06
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/840,699 10/725,267
		Filing Date	03/29/2001
Date Submitted: (use as many sheets as necessary)		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned 1624
Sheet 7 of 14		Examiner Name	Unassigned T. TRUONG
		Attorney Docket Number	034536-0906

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Exami ner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
TNT	A73	GAZIT et al., "Tyrophostins. 2. Heterocyclic and α -Substituted Benzylidenemalononitrile Tyrophostins as Potent Inhibitors of EGF Receptor and ErbB2/neu Tyrosine Kinases," <u>J. Med. Chem.</u> 34:1896-1907 (1991) copyright Am. Chem. Soc.	
	A74	GENNARO (editor), <u>Remington's Pharmaceutical Sciences</u> (1990) (TABLE OF CONTENTS ONLY), Mack Pub. Co., Easton, PA.	
	A75	GOLDRING and GOLDRING, "Cytokines and Cell Growth Control," <u>Critical Reviews in Eukaryotic Gene Expression</u> 1:301-326 (1991).	
	A76	GRAZIANI et al., "Hepatocyte Growth Factor/Scatter Factor Stimulates the Ras-Guanine Nucleotide Exchanger," <u>The Journal of Biological Chemistry</u> 268:9165-9168 (1993) © American Society for Biochemistry and Molecular Biology.	
	A77	HONEGGER et al., "Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Activity and Alters Cellular Routing," <u>Cell</u> 51:199-209 (1987) © Cell Press.	
	A78	HOUCK et al., "Dual Regulation of Vascular Endothelial Growth Factor Bioavailability by Genetic and Proteolytic Mechanisms," <u>J. Biol. Chem.</u> 267:26031-26037 (1992) © American Society for Biochemistry and Molecular Biology, Inc.	
	A79	HU et al., "Interaction of Phosphatidylinositol 3-Kinase-Associated p85 with Epidermal Growth Factor and Platelet-Derived Growth Factor Receptors," <u>Molecular and Cellular Biology</u> 12:981-990 (1992) copyright Am. Soc. Microbiol.	
	A80	JELLINEK et al., "Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor," <u>Biochemistry</u> 33:10450-10456 (1994) © American Chemical Society.	
TNT	A81	KASHISHIAN and COOPER, "Phosphorylation Sites at the C-terminus of the Platelet-Derived Growth Factor Receptor Bind Phospholipase C γ 1," <u>Molecular Biology of the Cell</u> 4:49-57 (1993) © The American Society for Cell Biology.	

Examiner Signature		Date Considered	2/3/06
-----------------------	--	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: (use as many sheets as necessary)		Complete if Known Application Number <u>00/840,608 10/725,267</u> Filing Date <u>03/29/2001</u> First Named Inventor <u>Peng Cho TANG</u> Group Art Unit <u>Unassigned 1624</u> Examiner Name <u>Unassigned T. TRUONG</u> Attorney Docket Number <u>034536-0906</u>	
Sheet	8	of	14

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
TMT ✓	A82	KASHISHIAN et al., "Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and PI3 kinase <i>in vivo</i> ," <u>The EMBO Journal</u> 11:1373-1382 (1992) .	
✓	A83	KATO et al., "Simultaneous Determination of Amfenac Sodium and its Metabolite (7-Benzoyl-2-Oxindole) in Human Plasma by High-Performance Liquid Chromatography," <u>Journal of Chromatography</u> 616:67-71 (1993) ©Elsevier Science .	
✓	A84	KAZLAUSKAS et al., "The 64-kDa protein that associates with the platelet-derived growth factor receptor β subunit via Tyr-1009 is the SH2-containing phosphotyrosine phosphatase Syp," <u>Proc. Natl. Acad. Sci. USA</u> 90:6939-6942 (1993) .	
✓	A85	KENDALL and THOMAS, "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor," <u>Proc. Natl. Acad. Sci. USA</u> 90:10705-10709 (1993) .	
✓	A86	KIM et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth <i>in vivo</i> ," <u>Nature</u> 362:841-844 (1993) .	
✓	A87	KINSELLA et al., "Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel," <u>Exp. Cell Research</u> 199:58-62 (1992) © Academic Press, Inc.	
✓	A88	KLGSBRUN and SOKER, "VEGF/VPF: the angiogenesis factor found?" <u>Current Biology</u> 3:699-702 (1993) ©Current Biology .	
✓	A89	KOCH et al., "SH2 and SH3 Domains: Elements That Control Interactions of Cytoplasmic Signaling Proteins," <u>Science</u> 252:668-674 (1991) .	
TMT ✓	A90	KOMADA and KITAMURA, "The cell dissociation and motility triggered by scatter factor/hepatocyte growth factor are mediated through the cytoplasmic domain of the c-Met receptor," <u>Oncogene</u> 8:2381-2390 (1993).	

Examiner Signature		Date Considered	2/3/06
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. *See attached Kinds of U.S. Patent Documents. ²Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ³For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁵Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: (use as many sheets as necessary)		Application Number	06/010,698- 10/725,267
		Filing Date	03/29/2001
		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned 1624
		Examiner Name	Unassigned T. TRUONG
Sheet 9 of 14	Attorney Docket Number	034536-0906	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
TNT	A91	KORC et al., "Overexpression of the Epidermal Growth Factor Receptor in Human Pancreatic Cancer Is Associated with Concomitant Increases in the Levels of Epidermal Growth Factor and Transforming Growth Factor Alpha," <u>J. Clin. Invest.</u> 90:1352-1360 (1992) copyright The American Society for Clinical Investigation, Inc.	
	A92	KORZENIEWSKI and CALLEWAERT, "An Enzyme-Release Assay for Natural Cytotoxicity," <u>J. Immunol. Methods</u> 64:313-320 (1983) © Elsevier Science Publishers .	
	A93	KUMABE et al., "Amplification of α -platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin," <u>Oncogene</u> 7:627-633 (1992) .	
	A94	LEE and DONOGHUE, "Intracellular Retention of Membrane-Anchored v-s/s Protein Abrogates Autocrine Signal T transduction," <u>J. Cell. Biol.</u> 118:1057-1070 (1992) ©The Rockefeller University Press .	
	A95	LEVITZKI and GAZIT, "Tyrosine Kinase Inhibition: An Approach to Drug Development," <u>Science</u> 267:1782-1788 (1995) .	
	A96	MAASS et al., "Viral Resistance to the Thiazolo-Iso-Indolinones, a New Class of Nonnucleoside Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase," <u>Antimicrobial Agents and Chemotherapy</u> 37:2612-2617 (1993) ©American Society for Microbiology .	
	A97	MACAULAY et al., "Autocrine Function for Insulin-like Growth Factor I in Human Small Cell Lung Cancer Cell Lines and Fresh Tumor Cells," <u>Cancer Research</u> 50:2511-2517 (1990) .	
	A98	MARIANI et al., "Inhibition of angiogenesis by FCE 26806, a potent tyrosine kinase inhibitor," <u>Experimental Therapeutics - Proceedings of the American Association for Cancer Research</u> 35:381 at abstract no. 2268 (March 1994) .	
TNT	A99	MILLAUER et al., "High Affinity VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenesis," <u>Cell</u> 72:835-846 (1993) © Cell Press .	

Examiner Signature		Date Considered	2/3/06
--------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	00/840,600 10/725,267
		Filing Date	03/29/2001
Date Submitted: (use as many sheets as necessary)		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned
Sheet 10 of 14		Examiner Name	Unassigned T. TRUONG
		Attorney Docket Number	034536-0906

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
TM	A100	MOHAMMADI et al., "Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors," <u>Science</u> 276:955-960 (1997) © American Association for the Advancement of Science .	
	A101	MORETO et al., "Study of the Laxative Properties of the Disodium Salt of the Sulfuric Diester of 3,3 Bis-(4-Hydroxyphenyl)-7-Methyl-2-Indolinone (DAN-603) in the Rat," <u>European Journal of Pharmacology</u> 36:221-226 (1976) ©North-Holland Publishing Company .	
	A102	MORETO et al., "3,3-Bis-(4-Hydroxyphenyl)-7-Methyl-2-Indolinone (BHMI), the Active Metabolite of the Laxative Sulisatin," <u>Arzneimittel-Forschung Drug Research</u> 29:1561-1564 (1979) .	
	A103	MORRISON et al., "Signal Transduction From Membrane to Cytoplasm: Growth Factors and Membrane-Bound Oncogene Products Increase Raf-1 Phosphorylation and Associated Protein Kinase Activity," <u>Proc. Natl. Acad. Sci. USA</u> 85:8855-8859 (1988) .	
	A104	MOSMANN, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays," <u>J. Immunol. Methods</u> 65:55-63 (1983) copyright Elsevier Publishers B.V.	
	A105	NISHIMURA et al., "Two Signaling Molecules Share a Phosphotyrosine-Containing Binding Site in the Platelet-Derived Growth Factor Receptor," <u>Molecular and Cellular Biology</u> 13:6889-6896 (1993) .	
	A106	PLOWMAN et al., "Receptor Tyrosine Kinases as Targets for Drug Intervention," <u>DN&P</u> 7:334-339 (1994) .	
	A107	QUINN et al., "Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium," <u>Proc. Natl. Acad. Sci. USA</u> 90:7533-7537 (1993) .	
TM	A108	ROZAKIS-ADCOCK et al., "Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases," <u>Nature</u> 360:689-692 (1992) .	

Examiner Signature		Date Considered	2/3/06
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: (use as many sheets as necessary)		Application Number	09/840,698 10/725,267
		Filing Date	03/29/2001
		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned 1624
		Examiner Name	Unassigned T. TRUONG
Sheet 11 of 14	Attorney Docket Number	034536-0906	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
TNT	A109	RYGAARD and POVLSEN, "Heterotransplantation of a Human Malignant Tumour to 'Nude' Mice," <u>Acta Path. Microbiol. Scand.</u> 77:758-760 (1969) .	
	A110	SANDBERG-NORDQVIST et al., "Characterization of Insulin-Like Growth Factor 1 in Human Primary Brain Tumors," <u>Cancer Research</u> 53:2475-2478 (1993) .	
	A111	SCHLESSINGER and ULLRICH, "Growth Factor Signalling by Receptor Tyrosine Kinases," <u>Neuron</u> 9:383-391 (1992) © Cell Press .	
	A112	SHIBUYA et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family," <u>Oncogene</u> 5:519-524 (1990) .	
	A113	SHIRAISHI et al., "Specific inhibitors of Tyrosine-Specific Protein Kinase, Synthetic 4-Hydroxycinnamamide Derivatives," <u>Biochemical and Biophysical Research Communications</u> 147:322-328 (1987)© Academic Press .	
	A114	SINGH et al., "Indolinone Derivatives as Potential Antimicrobial Agents," <u>Zentralbl. Mikrobiol.</u> 144:105-109 (1989) copyright VEB Gustav Fischer Verlag Jena .	
	A115	SINGH et al., "Synthesis and Anticonvulsant Activity of New 1-Substituted 1'-Methyl-3-Chloro-2-Oxospiro (Azetidin-3', 4-Indol-2' Ones)," <u>Bollettino Chimico Farmaceutico</u> 133:76-79 (1994) .	
	A116	SINKULA, "Prodrug Approach in Drug Design," <u>Medicinal Chemistry</u> , Vol. 10, pp. 306-315, 1975, ©Academic Press .	
TNT	A117	SLAMON et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer," <u>Science</u> 244:707-712 (1989) .	

Examiner Signature		Date Considered	2/3/06
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/849,898- 10/725,267
		Filing Date	03/29/2001
Date Submitted:		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned 1624
(use as many sheets as necessary)		Examiner Name	Unassigned T. TRUONG
Sheet	12	of	14
		Attorney Docket Number	034536-0906

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Exami ner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
TNT	A118	SOLDI et al., "Platelet-Activating Factor (PAF) Induces the Early Tyrosine Phosphorylation of Focal Adhesion Kinase (p125 ^{FAK}) in Human Endothelial Cells," <u>Oncogene</u> 13:515-525 (1996) copyright Stockton Press .	
	A119	SONGYANG et al., "SH2 Domains Recognize Specific Phosphopeptide Sequences," <u>Cell</u> 72:767-778 (1993) © Cell Press .	
	A120	SONGYANG et al., "Specific Motifs Recognized by the SH2 Domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk and Vav," <u>Molecular and Cellular Biology</u> 14:2777-2785 (1994) © American Society for Microbiology .	
	A121	SPADA, et al., "Small molecule inhibitors of tyrosine kinase activity," <u>Expert Opinion on Therapeutic Patents</u> 5:805-817 (1995) ©Ashley Publications .	
	A122	SUN et al, "Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases," <u>J. Med. Chem.</u> 41:2588-2603 (1998) ©The American Chemical Society .	
	A123	SUPERTI-FURGA et al., "A functional screen in yeast for regulators and antagonizers of heterologous protein tyrosine kinases," <u>Nature Biotech.</u> 14:600-605 (1996) .	
	A124	SUPERTI-FURGA et al., "Csk inhibition of c-Src activity requires both the SH2 and SH3 domains of Src," <u>EMBO J.</u> 12:2625-2634 (1993) © Oxford University Press .	
	A125	TAKANO et al., "Inhibition of angiogenesis by a novel diaminoanthraquinone that inhibits Protein Kinase C," <u>Mol. Bio. Cell</u> 4:358A at abstract no. 2076 (1993) .	
TNT	A126	TORP et al., "Expression of the Epidermal Growth Factor Receptor Gene in Human Brain Metastases," <u>APMIS</u> 100:713-719 (1992) .	

Examiner Signature		Date Considered	2/3/06
-----------------------	---	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	20/849,608 10/725,267
		Filing Date	03/29/2001
Date Submitted: (use as many sheets as necessary)		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned 1624
Sheet 13 of 14		Examiner Name	Unassigned T. TRUONG
		Attorney Docket Number	034536-0906

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁴
TNT	A127	TRAXLER, "Protein tyrosine kinase inhibitors in cancer treatment," <u>Expert Opinion on Therapeutic Patents</u> 7(6):571-588 (1997) © Ashley Publications Ltd.	
	A128	TROST et al. (ed.), <u>Comprehensive Organic Synthesis. Selectivity, Strategy & Efficiency in Modern Organic Chemistry</u> , 4:477-480 (1991), Elsevier Science Ltd.	
	A129	TSAI et al., "The Effect of 3,3-Di-Pyridyl Methyl-1-Phenyl-2-Indolinone on the Nerve Terminal Currents of Mouse Skeletal Muscles," <u>Neuropharmacology</u> 31:943-947 (1992) © Pergamon Press.	
	A130	TUZI et al., "Expression of growth factor receptors in human brain tumours," <u>Br. J. Cancer</u> 63:227-233 (1991).	
	A131	TWAMLEY-STEIN et al., "The Src family tyrosine kinases are required for platelet-derived growth factor-mediated signal transduction in NIH 3T3 cells," <u>Proc. Natl. Acad. Sci. USA</u> 90:7696-7700 (1993).	
	A132	VAISMAN et al., "Characterization of the Receptors for Vascular Endothelial Growth Factor," <u>J. Biol. Chem.</u> 265:19461-19466 (1990) © The American Society for Biochemistry and Molecular Biology.	
	A133	VARMA and GUPTA, "Nucleophilic Reactions of 2-Methyl-3-(4'-carbomethoxyphenyl)-4-quinazolinones with 2-Indolinones," <u>J. Indian Chem. Soc.</u> 66:804-805 (1989) © The Indian Chemical Society.	
	A134	VOLLER et al., "Ch. 45 - Enzyme-Linked Immunosorbent Assay," in <u>Manual of Clinical Immunology</u> , 2 nd edition, Rose and Friedman editors, American Society of Microbiology, Washington, D.C., pp. 359-371 (1980); © American Society for Microbiology.	
TNT	A135	WALKER et al., "Synthesis of New 3-(Pyridylmethylene)-, 3-(Pyridylmethyl)-, 3-(Piperidylmethyl)-, and 3-(β-Alkylaminoethyl)-2-indolinones. The Reduction of Isoindogenides, Nitro Compounds, and Pyridines in a Series of 2-Indolinones," <u>J. Med. Chem.</u> 8:626-637 (1965).	

Examiner Signature		Date Considered	2/3/06
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.


⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/019,598 10/725,267
		Filing Date	03/29/2001
Date Submitted: (use as many sheets as necessary)		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned 1624
Sheet 14 of 14		Examiner Name	Unassigned T. TRUONG
		Attorney Docket Number	034536-0906

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
TNT	A136	WEIDNER et al., "Tumor Angiogenesis and Metastasis - Correlation in Invasive Breast Carcinoma," <u>New England J. Medicine</u> 324:1-7 (1991) © Massachusetts Medical Society .	
✓	A137	WRIGHT et al., "Inhibition of Angiogenesis in Vitro and In Ovo With an Inhibitor of Cellular Protein Kinases, MDL 27032," <u>J. Cellular Physiology</u> 152:448-457 (1992) .	
✓	A138	ZAMAN et al., "Tyrosine Kinase Activity of Purified Recombinant Cytoplasmic Domain of Platelet-Derived Growth Factor β-Receptor (β-PDGFR) and Discovery of a Novel Inhibitor of Receptor Tyrosine Kinases," <u>Biochemical Pharmacology</u> 57:57-64 (1999) ©Elsevier Science Inc.	
TNT	A139	ZHANG et al., "Microtubule Effects of Welwistatin, a Cyanobacterial Indolinone that Circumvents Multiple Drug Resistance," <u>Molecular Pharmacology</u> 49:228-234 (1996) ©The American Society for Pharmacology and Experimental Pharmacautics .	

Examiner Signature		Date Considered	2/3/06
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/725,267
				Filing Date	12/02/2003
				First Named Inventor	Peng Cho TANG
				Group Art Unit	1624
				Examiner Name	Unassigned
(use as many sheets as necessary)				Attorney Docket Number	034536-0906
Sheet	1	of	1		



U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns/Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
TNT	B1	6,677,368	B2	CUI et al.	01-13-2004	see attached sheet for classification
	B2	6,642,232	B2	MATTSON et al.	11-04-2003	
	B3	6,635,640	B2	TANG et al.	10-21-2003	
	B4	6,486,185	B1	McMAHON et al.	11-26-2002	
	B5	6,395,734	B1	TANG et al.	05-28-2002	
	B6	6,316,635	B1	TANG et al.	11-13-2001	
TNT	B7	6,313,158	B1	TANG et al.	11-06-2001	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		
TNT	B8	BENNETT and PLUM (Eds.), <u>Cecil Textbook of Medicine</u> , 20 th Ed., Vol. 1, 1996, pp. 1004-1010, W.B. Saunders Company		
	B9	WOLFF (Ed.), <u>Burger's Medicinal Chemistry and Drug Discovery</u> , 5 th Ed., Vol. 1: Principles and Practice, 1995, pp. 975-977, John Wiley & Sons		
	B10	HASAN, "VEGF antagonists," <u>Expert Opin. Biol. Ther.</u> , July 2001, pp. 703-718, Vol. 1, No. 4, ABSTRACT ONLY		
TNT	B11	PEGGRAM et al., "Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor," <u>Semin. Oncol.</u> , June 2002, pp. 29-37, Vol. 3, Suppl. 11, ABSTRACT ONLY		

Examiner Signature		Date Considered	2/3/06
--------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.